Advanced cholangiocarcinoma treated with gemcitabine combined with 5-FU: An initial study of short-term therapeutic effect
	    		
		   		
	    	
    	
    	
   		
        
        	
        		- VernacularTitle:吉西他滨联合氟尿嘧啶治疗晚期肝外胆管癌
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Mei WANG
			        		
			        		;
		        		
		        		
		        		
			        		Biao GONG
			        		
			        		;
		        		
		        		
		        		
			        		Bin JIANG
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		cholangiocarcinoma;
			        		
			        		
			        		
				        		gemcitabine;
			        		
			        		
			        		
				        		5-fluororacil;
			        		
			        		
			        		
				        		combined chemotherapy
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			China Oncology
	            		
	            		 2001;0(03):-
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Purpose:To observe the therapeutic effect of gemcitabine combined with 5-FU for the treatment of advanced cholangiocarcinoma. Methods:21 patients were given gemcitabine and 5-FU intravenously. Results:There was no complete response .The partial response rate was 23.8% and SD,38.1%.12 patients(57.14%) had amelioration of pain and improvement in quality of life.The toxicity was low and tolerable. Conclusions:Gemcitabine combined with 5-FU was an effective and safe regimen for treating advanced cholangiocarcinoma and worthy of further evaluation.